Search
Cardiolipin Biosynthesis CL(10:0/14:0/20:0/20:0)
smpdb.ca/view/SMP0177564MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/20:0/21:0)
smpdb.ca/view/SMP0178970MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/20:0/22:0)
smpdb.ca/view/SMP0178971MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/20:0/23:0)
smpdb.ca/view/SMP0178972MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/20:0/20:0/25:0)
smpdb.ca/view/SMP0178974MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigational[L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin
Products: BRAFTOVI® 75 MG CÁPSULAS, BRAFTOVİ 75 MG SERT KAPSÜL, 42 ADETApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApproximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].
Categories: MATE 2 Inhibitors, MATE 1 InhibitorsProducts: ERLEADA ®TABLETAS RECUBIERTAS 60 MGRegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalFDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.
Categories: Heterocyclic Compounds, 1-RingProducts: STIVARGA 40 MG TABLETA RECUBIERTA, STIVARGA 40 MG FILM KAPLI TABLET ,84 ADETTetanus immune globulin, human
go.drugbank.com/drugs/DB11604ApprovedInvestigationalIt contains antibodies against tetanus toxoid and is primarily used as prophylaxis against tetanus in wounded patients.
Products: TETANUS GAMMA KEDRION ® 250 UI/1 ML, TETAGAM P 250 IU/1 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİReboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD.
Categories: Heterocyclic Compounds, 1-RingProducts: EDRONAX 4 MG TABLET, 60 ADET, Edronax 4 mg - Tabletten